• A recent precedential decision, issued by the Compensation and Royalties Committee (“the Committee”), in a case in which our firm represented a leading Israeli company, highlights the potential role of collective agreements, or collective arrangements, in reducing the exposure of companies conducting R&D in Israel to claims by their employees for compensation for service inventions. The decision could encourage companies engaging in R&D activities in Israel to consider collective regulation of their employees' right to seek compensation for service inventions, for example by adopting appropriate internal regulations.

  • The medical device industry is one of the most important and innovative sectors in Israel. The Israeli regulatory regime covering medical devices is governed by the Medical Devices Law, 2012 (“the Medical Device Law”) and the Medical Device Regulations (Registration of a Medical Device and the Renewal Thereof), 2013. However, the Medical Device Law is not yet formally in force, since the enactment of further regulations is still required. However, in practice, the principles of the Medical Device Law are applied by the Ministry of Health, in accordance with certain administrative circulars. To read the full article click on the Headline.

  • There has been a dramatic decision by the Supreme Court in Israel —the damage caused to Israeli consumers due to the operation of an international cartel among foreign companies, does not constitute an “act or omission” that occurred in Israel. Click below to read the full article >>

  • A New Era for Designers (English)

    S. Horowitz & Co.

    By Avi Ordo, Noam Blei

    Finally, after a lengthy legislation process, on July 26. 2017 the Knesset approved the Designs Law, 2017. The Designs Law replaces the main legal arrangement, which governed for over 90 years the protection of industrial designs in Israel - The Patents and Designs Ordinance of 1924, by a more modern and updated arrangement. To read the full Article click here >>

  • The new Designs Bill, which was enacted on Wednesday, brings a host of significant improvements for the designers. The Bill will replace the old Patent and Design Ordinance that was previously the legal basis for design registration and protection in Israel since 1924. To read the full Article click here >>

  • The Israeli chapter in the book The Life Sciences Law Review (5th edition, 2017), authored by Dovev Apel, provides a unique overview of the regulatory regimen relating to the life sciences industry in Israel. The updated chapter contains review of the substantial amendment recently introduced to the Pharmacists Ordinance ¬– the primary piece of legislation regulating medicinal preparations in Israel – which recently entered into force. Dovev was highly involved in the legislation process. To read the full Article click here >>

  • S. Horowitz & Co. has recently been published in the American Bar Association (ABA) Section of International Law, discussing one of the ‘hot topics’ in international antitrust law. Chair of the firm’s Antitrust & Competition Law Practice Group, Hagai Doron taps into his role as counsel to one of the appellants in a groundbreaking case to elaborate on the complexities arising when the issues of global cartels, class actions and jurisdictions overlap. Widely considered by domestic and international legal directories as one of the prominent antitrust and competition practitioners in Israel, Hagai impresses with his "creative thinking and legal strategy,"(Legal 500) and as a "dedicated and highly professional lawyer" (Chambers Global).” To read more click here>>

  • The Israeli government has approved a new bill, proposing amendments to Chapter E2 of the Income Tax Ordinance (New Version), 1961, which deals with tax reliefs for restructuring and merger transactions. The proposed amendments include moderations of the conditions and limitations under which mergers and restructures qualify for tax exemptions and reliefs, and they are expected to have a positive impact on the Israeli market in general and the hi-tech industry in particular.

  • The issue of forced retirement due to age raises constitutional questions of the first order specifically regarding the constitutional right to: liberty; dignity and property; freedom of occupation; and equality in general and in the workplace in particular. Forced retirement due to age was abolished decades ago in the United States and has also been abolished in Australia, Canada and the United Kingdom. However, the Organisation for Economic Cooperation and Development enables member states to enact forced retirement due to age based on legitimate concerns, such as the necessity to regenerate the market and the workplace. Despite age being recognised as an unlawful and irrelevant criterion for employment in most anti-discrimination legislation in Israel and substantial case law, the Retirement Age Law 2004 allows employers forcibly to retire employees at the age of 67, the mandatory retirement age.

  • Whistleblowers often claim that they were dismissed due to their whistleblowing activities and are therefore entitled to the special statutory compensation intended to protect whistleblowers. Without attempting to exhaust all the intricacies of such a claim, it must be remembered that even if an employee is convinced that the irregularities cautioned against occurred and is genuinely displeased by them, he or she must exercise caution as unrestrained conduct could lead to lawful dismissal.